{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:55:12Z","timestamp":1790686512814,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2307601"],"award-info":[{"award-number":["2023YFC2307601"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Modelling"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.idm.2026.03.003","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T16:22:43Z","timestamp":1772900563000},"page":"1022-1033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A predictive model for rapid assessment of protective efficacy against emerging SARS-CoV-2 variants"],"prefix":"10.1016","volume":"11","author":[{"given":"Lairun","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyue","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwei","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7033-5151","authenticated-orcid":false,"given":"Jingxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.idm.2026.03.003_bib1","doi-asserted-by":"crossref","first-page":"e02107","DOI":"10.1128\/JCM.02107-20","article-title":"Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate","volume":"58","author":"Addetia","year":"2020","journal-title":"Journal of Clinical Microbiology"},{"issue":"16","key":"10.1016\/j.idm.2026.03.003_bib2","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.idm.2026.03.003_bib3","first-page":"276","article-title":"The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series","volume":"42","author":"Angkasekwinai","year":"2024","journal-title":"Asian Pacific Journal of Allergy & Immunology"},{"issue":"1","key":"10.1016\/j.idm.2026.03.003_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.126","article-title":"SARS-CoV-2 omicron variant: Immune escape and vaccine development","volume":"3","author":"Ao","year":"2022","journal-title":"MedComm"},{"issue":"5","key":"10.1016\/j.idm.2026.03.003_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.idm.2026.03.003_bib6","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1097\/MS9.0000000000002391","article-title":"Disease X and COVID-19: Turning lessons from India and the world into policy recommendations","volume":"86","author":"Bardhan","year":"2024","journal-title":"Annals of Medicine and Surgery"},{"issue":"12","key":"10.1016\/j.idm.2026.03.003_bib7","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1586\/14760584.2015.1091733","article-title":"The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials","volume":"14","author":"Black","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"10.1016\/j.idm.2026.03.003_bib8","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41591-022-01877-1","article-title":"Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance","volume":"28","author":"Cao","year":"2022","journal-title":"Nature Medicine"},{"issue":"3","key":"10.1016\/j.idm.2026.03.003_bib9","first-page":"162","article-title":"SARS-CoV-2 variant biology: Immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nature Reviews Microbiology"},{"issue":"1","key":"10.1016\/j.idm.2026.03.003_bib10","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1038\/s41467-022-31839-7","article-title":"Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil","volume":"13","author":"Cerqueira-Silva","year":"2022","journal-title":"Nature Communications"},{"issue":"4","key":"10.1016\/j.idm.2026.03.003_bib11","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41591-022-01701-w","article-title":"Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil","volume":"28","author":"Cerqueira-Silva","year":"2022","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1016\/j.idm.2026.03.003_bib12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa","volume":"386","author":"Collie","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.idm.2026.03.003_bib13","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cell.2023.02.001","article-title":"A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike","volume":"186","author":"Dadonaite","year":"2023","journal-title":"Cell"},{"issue":"32","key":"10.1016\/j.idm.2026.03.003_bib14","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"issue":"10317","key":"10.1016\/j.idm.2026.03.003_bib15","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.idm.2026.03.003_bib17","series-title":"Emergency use authorization for vaccines to prevent COVID-19","year":"2022"},{"issue":"10249","key":"10.1016\/j.idm.2026.03.003_bib18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.idm.2026.03.003_bib19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cell.2020.12.015","article-title":"COVID-19-neutralizing antibodies predict disease severity and survival","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"issue":"6576","key":"10.1016\/j.idm.2026.03.003_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"issue":"20","key":"10.1016\/j.idm.2026.03.003_bib21","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - Preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.idm.2026.03.003_bib22","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S2214-109X(22)00112-7","article-title":"Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: A large-scale prospective cohort study","volume":"10","author":"Jara","year":"2022","journal-title":"Lancet Global Health"},{"issue":"12","key":"10.1016\/j.idm.2026.03.003_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011868","article-title":"Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 synergistically enhances antibody evasion and ACE2 binding","volume":"19","author":"Jian","year":"2023","journal-title":"PLoS Pathogens"},{"issue":"8","key":"10.1016\/j.idm.2026.03.003_bib24","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41564-025-02030-7","article-title":"Viral evolution prediction identifies broadly neutralizing antibodies to existing and prospective SARS-CoV-2 variants","volume":"10","author":"Jian","year":"2025","journal-title":"Nature Microbiology"},{"key":"10.1016\/j.idm.2026.03.003_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanwpc.2023.100829","article-title":"Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): A phase 4, randomised, observer-blind, non-inferiority trial","volume":"38","author":"Jin","year":"2023","journal-title":"Lancet Regional Health. Western Pacific"},{"issue":"1","key":"10.1016\/j.idm.2026.03.003_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2022.2155251","article-title":"Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial","volume":"12","author":"Jin","year":"2023","journal-title":"Emerging Microbes & Infections"},{"issue":"10","key":"10.1016\/j.idm.2026.03.003_bib27","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S1473-3099(23)00553-4","article-title":"Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5","volume":"23","author":"Kaku","year":"2023","journal-title":"The Lancet Infectious Diseases"},{"issue":"24","key":"10.1016\/j.idm.2026.03.003_bib28","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.idm.2026.03.003_bib29","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nature Medicine"},{"issue":"10","key":"10.1016\/j.idm.2026.03.003_bib30","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1473-3099(23)00350-X","article-title":"Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: A multicentre, open-label phase 3 trial","volume":"23","author":"Li","year":"2023","journal-title":"The Lancet Infectious Diseases"},{"issue":"2","key":"10.1016\/j.idm.2026.03.003_bib31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-021-01677-z","article-title":"Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: A randomized phase 4 trial","volume":"28","author":"Li","year":"2022","journal-title":"Nature Medicine"},{"issue":"8","key":"10.1016\/j.idm.2026.03.003_bib32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","article-title":"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: A randomised, open-label, single-centre trial","volume":"10","author":"Li","year":"2022","journal-title":"Lancet Respiratory Medicine"},{"issue":"1","key":"10.1016\/j.idm.2026.03.003_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-025-01066-4","article-title":"mRNA vaccines with RBD mutations have broad-spectrum activity against SARS-CoV-2 variants in mice","volume":"10","author":"Liang","year":"2025","journal-title":"npj Vaccines"},{"issue":"1","key":"10.1016\/j.idm.2026.03.003_bib34","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1038\/s41467-023-37926-7","article-title":"Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants","volume":"14","author":"Liu","year":"2023","journal-title":"Nature Communications"},{"issue":"10275","key":"10.1016\/j.idm.2026.03.003_bib35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"issue":"10255","key":"10.1016\/j.idm.2026.03.003_bib36","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.idm.2026.03.003_bib37","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2034545","article-title":"Antibody status and incidence of SARS-CoV-2 infection in health care workers","volume":"384","author":"Lumley","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"10327","key":"10.1016\/j.idm.2026.03.003_bib38","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0140-6736(22)00089-7","article-title":"Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: A retrospective, total population cohort study in Sweden","volume":"399","author":"Nordstr\u00f6m","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.idm.2026.03.003_bib40","author":"Pearson"},{"issue":"27","key":"10.1016\/j.idm.2026.03.003_bib41","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.idm.2026.03.003_bib42","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2666-5247(23)00012-5","article-title":"Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): A prospective cohort study","volume":"4","author":"Regev-Yochay","year":"2023","journal-title":"The Lancet Microbe"},{"issue":"7","key":"10.1016\/j.idm.2026.03.003_bib43","doi-asserted-by":"crossref","first-page":"Jc75","DOI":"10.7326\/ACPJ202107200-075","article-title":"The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at \u226514 d","volume":"174","author":"Sacks","year":"2021","journal-title":"Annals of Internal Medicine"},{"issue":"19","key":"10.1016\/j.idm.2026.03.003_bib44","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.idm.2026.03.003_bib45","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/22221751.2022.2037398","article-title":"Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: A test-negative case-control study","volume":"11","author":"Sritipsukho","year":"2022","journal-title":"Emerging Microbes & Infections"},{"issue":"7","key":"10.1016\/j.idm.2026.03.003_bib46","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/vaccines10071080","article-title":"Real-World effectiveness of mix-and-match vaccine regimens against SARS-CoV-2 Delta variant in Thailand: A nationwide test-negative matched case-control study","volume":"10","author":"Suphanchaimat","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1016\/j.idm.2026.03.003_bib47","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S2213-2600(23)00049-8","article-title":"Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: A multicentre, open-label, phase 4, randomised trial","volume":"11","author":"Tang","year":"2023","journal-title":"Lancet Respiratory Medicine"},{"issue":"10269","key":"10.1016\/j.idm.2026.03.003_bib48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.idm.2026.03.003_bib49","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.idm.2026.03.003_bib50","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/s41467-021-21444-5","article-title":"Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19","volume":"12","author":"Wheatley","year":"2021","journal-title":"Nature Communications"},{"issue":"2","key":"10.1016\/j.idm.2026.03.003_bib53","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S1473-3099(23)00744-2","article-title":"Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure","volume":"24","author":"Yang","year":"2024","journal-title":"The Lancet Infectious Diseases"},{"issue":"2","key":"10.1016\/j.idm.2026.03.003_bib54","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"The Lancet Infectious Diseases"}],"container-title":["Infectious Disease Modelling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468042726000187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468042726000187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:01:08Z","timestamp":1790683268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468042726000187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2468042726000187"],"URL":"https:\/\/doi.org\/10.1016\/j.idm.2026.03.003","relation":{},"ISSN":["2468-0427"],"issn-type":[{"value":"2468-0427","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A predictive model for rapid assessment of protective efficacy against emerging SARS-CoV-2 variants","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Modelling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idm.2026.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}